-
Doctors top career rankings related to overall risk of prostate cancer!
Time of Update: 2022-03-04
81]) between overall PCa risk and specific occupations lasting 10 years or more (eg surveyors, draftsmen and related technicians ); medical, dental and veterinary work people (OR = 3.
-
Clinical Colorectal Cancer: Real-world data from the Beijing Cancer Hospital team show that regorafenib and fruquintinib are equally effective in the treatment of metastatic colorectal cancer
Time of Update: 2022-03-04
colorectal cancerPatients with metastatic CRC who received regorafenib or fruquintinib between January 2018 and April 2020 were retrospectively collected, and patients treated between May 2020 and February 2021 were prospectively included .
-
Transl Lung Cancer Res: Efficacy of second-line docetaxel + ramucirumab in patients with metastatic NSCLC without driver mutation
Time of Update: 2022-03-04
Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation .
Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation .
-
Transl Lung Cancer Res: The Huaxi team showed that the use of video-assisted thoracoscopy (VATS) and thoracotomy (OT) for lobectomy and PAA in patients with lung cancer are comparable
Time of Update: 2022-03-04
Studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients .
Studies have shown that video-assisted thoracoscopy (VATS) is comparable to thoracotomy (OT) for lobectomy and PAA in the treatment of lung cancer patients .
-
European Radiology: Multiparametric MRI-based radiomics for preoperative prediction of extraluminal vein invasion in rectal cancer
Time of Update: 2022-03-04
He developed and validated a combined model for EMVI assessment with histological , clinical, and imaging features, providing technical support for prognostic prediction in the formulation of individualized treatment regimens for rectal cancer patients .
-
Nanjing Legend Bio has suspended the phase I clinical trial of CAR-T therapy LB1901
Time of Update: 2022-03-04
Nanjing Legend Biotech said recently that the FDA has informed the agency that it has suspended the Phase I trial of its autologous CAR-T therapy LB1901 .
com/story/5499517 https://firstwordpharma.
com/story/5499517 https://firstwordpharma.
-
Front Oncol: Exploring the optimal time point for local radiotherapy in patients with unresectable lung adenocarcinoma
Time of Update: 2022-03-04
Interestingly, for patients with bone metastases, mOS was significantly improved with early RT compared with delayed RT (56.
Interestingly, for patients with bone metastases, mOS was significantly improved with early RT compared with delayed RT (56.
-
Psychiatry Research: Single people are more likely to develop cancer and have higher mortality after cancer
Time of Update: 2022-03-04
The study showed that loneliness in middle-aged men was associated with an increased risk of cancer, and that single men (unmarried, widowed, divorced) had a higher mortality rate from cancer .
-
European Radiology: The role of texture features of ADC maps in predicting response to chemoradiotherapy in invasive bladder cancer
Time of Update: 2022-03-04
Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer .
1007/s00330-021-08110-6Koichiro Kimura Soichiro Yoshida Junichi Tsuchiya ,et al Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer 10.
-
Ann Oncol: Phase III BROCADE3 Study Shows Veliparib (Veliparib) Plus Carboplatin/Paclitaxel After Veliparib Maintenance Therapy Improves Outcomes in Patients With BRCA1/2 Germline Mutated Breast Cancer
Time of Update: 2022-03-04
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
-
Eur Urol Focus: What is the efficacy of nivolumab monotherapy in advanced renal cell carcinoma?
Time of Update: 2022-03-04
Manage ImmunizationRecently, researchers from Germany, published in Eur Urol Focus, conducted the NORA (NivOlumab in Renal cell cArcinoma) non-interventional study (NIS), which aims to obtain real-world data to complement the pivotal CheckMate 025 Clinical trial results .
-
Nature Communications: Unexpected: CRISPR gene editing causes heritable mutations in genome structure
Time of Update: 2022-03-04
Nature Communications CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generationsThe study confirmed that CRISPR-Cas9 gene editing results in unforeseen structural mutations in DNA that can be inherited by the next generation .
-
Sci Transl Med: Remove the "sugar coating" of tumor cells, and CAR-T becomes a "cannonball"!
Time of Update: 2022-03-04
By knocking out MGAT5 in pancreatic cancer ( PAC ), they found that N- glycans interfere with immune synapse formation, reduce transcriptional activation, cytokines and cytotoxicity, and protect tumors from CAR-T cell killing .
-
Target Oncol: FLAURA China Study Shows First-Line Osimertinib Improves Outcomes of EGFR-mutant NSCLC Patients in Chinese Population Compared with Gefitinib
Time of Update: 2022-03-04
Therefore, the domestic team carried out the FLAURA China study, mainly to evaluate the efficacy of osimertinib compared with the first-generation EGFR-TKIs in the first-line treatment of EGFRm NSCLC patients in the Chinese population .
-
Thorax: Incidence, treatment, and survival of malignant pleural and peritoneal mesothelioma
Time of Update: 2022-03-04
90%Recently, a research article was published in Thorax, an authoritative journal in the field of thoracic diseases, which aimed to review the population-based incidence, treatment and survival of MPM since asbestos was banned in the Netherlands in 1993 .
-
J Urol: Comparison of early outcomes between open radical cystectomy and robotic-assisted radical cystectomy
Time of Update: 2022-03-04
Oncological and functional outcomes need to be assessed at longer follow-up to see potential differences between groups This prospective randomized trial observed an overall perioperative transfusion rate of 22% and 41% in RARC and ORC-treated patients, respectively %, confirming the significant advantage of RARC with i-UD .
-
Eur Arch Otorhinolaryngol: Long-term Hearing Follow-up of Pediatric Platinum-Induced Ototoxicity
Time of Update: 2022-03-04
Recently, researchers from Italy published an article in "Eur Arch Otorhinolaryngol" on long-term hearing follow-up of platinum-induced ototoxicity in children .
Researchers from Italy, published in Eur Arch Otorhinolaryngol, conducted long-term hearing follow-up of pediatric platinum-induced ototoxicity Hearing follow-upThe study was a retrospective observational design .
-
Past and present life and important applications of amyloid A (SAA)
Time of Update: 2022-03-04
However, in the identification of different types of infections such as bacteria, fungi and viruses, the evaluation of antibiotic use and discontinuation, the evaluation of the severity of disease progression, and the diagnosis of early childhood infection [11] [11] [11] , A-SAA and other The combination of indicators plays an important role .
-
Ann Oncol: The efficacy of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed anti-PD-1
Time of Update: 2022-03-04
Recently, a phase II study was published in the journal Annals of Oncology evaluating the use of ceralasertib (AZD6738) in combination with the PD-L1 inhibitor durvalumab (Devalumab) in patients with advanced/metastatic melanoma who had failed PD-1 therapy.
-
Ann Oncol: Efficacy of nivolumab in unidentified primary tumors
Time of Update: 2022-03-04
The primary endpoint was objective response rate (ORR) in blinded independent center (BIRC)-assessed patients with previously treated CUP .
The primary endpoint was objective response rate (ORR) in blinded independent center (BIRC)-assessed patients with previously treated CUP .
